2009:

1. Medrano J, Barreiro P, Resino S, Tuma P, Rodriguez V, Vispo E, Labarga P, Madejon A, García-Samaniego J, Jímenez-Nácher I, Martín-Carbonero L and Soriano V. Hepatitis C virus (HCV) relapse following a successful course of pegylated interferon plus ribavirin therapy in HIV-infected and uninfected patients: rate, timing and predictors. Clin Infect Dis 2009. En prensa. (A; FI =8.26).

2. Micheloud D, González-Nicolás J, Berenguer J, Lorente R, Miralles P, López JC, Cosín J, Catalán P, Muñoz-Fernández MA, and Resino S. CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV co-infected patients. HIV Medicine 2009; En prensa (A; FI =3.10).

3. Resino S, Micheloud D, Miralles P, Bellón JM, Vargas A, Catalán P, Álvarez P, Cosín J, Lorente R, Carlos López J, Muñoz-Fernández M, and Berenguer J. Diagnosis of advanced fibrosis in HIV and HCV co-infected patients via a new non-invasive index: The HGM-3 index. HIV Medicine 2009; En prensa (A; FI =3.10).

4. Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, Resino S, Muñoz-Fernández M, and Leal M. Premature immunosenescence in HIV-infected patients on HAART with low-level CD4+ T repopulation. J Antimicrob Chemoth 2009 En prensa. (A; FI =4.32).

5. Micheloud D, Salcedo M, Bañares R, Rincon D, Jensen J, Rodriguez J, Fernandez-Cruz E, Carbone J, Resino S. High rate of infection and immune disorders in patients with Hepatitis C virus after liver transplantation. Transpl Infect Dis 2009; En prensa (A; FI =2.51).

6. Micheloud D, Salcedo M, Bañares R, Rincon D, Lorente R, Muñoz-Fernández MA, Resino S. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated to severe HCV recurrence. Transpl Infect Dis 2009; 11, 183-188 (A; FI =2.51).

7. Ryan P, Berenguer J, Michelaud D, Miralles P, Bellón JM, Alvarez E, Catalán P, Sánchez-Conde  M, and Resino S. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV coinfected patients. J Acquir Immune Defic Syndr 2009; 50(1): 109-110. (L; FI =4.57).

2008:

8. Resino S, Micheloud D, Larrú B, Bellón JM, Léon JA, Resino R, de José MI, Gurbindo D, Mellado MJ, Guillen S, Ramos JT, Muñoz-Fernández MA. Immunological recovery and metabolic disorders in severe immunodeficiency HIV-1 infected children on highly active antiretroviral therapy. AIDS Res Hum Retrov 2008; 24 (12): 1477-84. (A; FI =2.02).

9. Seoane E, Resino S, Micheloud D, Moreno A, Lopez Bernaldo de Quiros JC, Lorente R, Rubio R, Gonzalez J, Pulido F, Arribas JR, Moreno S, Muñoz-Fernández MA. Lipid and Apoprotein Profile in HIV-1-Infected Patients After CD4-Guided Treatment Interruption. J Acquir Immune Defic Syndr 2008;48:455–459 (A; FI =4.57).

10. Seoane E, Resino S, Moreno S, Lopez Bernaldo de Quiros JC, Moreno A, Rubio R, Gonzalez J, Pulido F, Muñoz-Fernández MA. Immunological predictors of CD4+ T Cell decline in antiretroviral treatment interruptions. BMC Inf Dis 2008;8(1):20 (A; FI =2.53).

11. Larrú B, Resino S, Bellón JM, de José MI, Fortuna C, Gurbindo MD, Soler P, Muñoz-Fernández MA. Long-term evolution of HIV and HCV coinfected children with HAART including lopinavir/ritonavir (LPV/r). Enferm Infecc Microbiol Clin 2008;26(7):426-9 (A; FI =1.43).

12. Micheloud D, Berenguer J, Bellón JM, Miralles P, Cosin J, Lopez-Bernaldo de Quiros JC, Sanchez-Conde M, Muñoz-Fernandez MA, Resino S. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naïve HIV-1-infected patients with severe immunodeficiency. J Infection 2008; 56: 130-136 (A; FI =3.09).

13. Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA. Long-term response to highly active antiretroviral therapy with lopinavir-ritonavir in pretreated vertically HIV-infected children. J Antimicrob Chemoth 2008; 61(1):183-190. (A; FI =4.32).

14. Berenguer J, Bellón JM, Miralles P, Alvarez A, Sánchez Conde M, Cosín J, López JC, Catalán P, Resino S. Association between Nevirapine exposure and reduced liver fibrosis progression and development of bridging fibrosis and cirrhosis in HIV/HCV-coinfected patients. Clin Infect Dis 2008; 46 (1): 137-143 (A; FI =8.26).

2007:

15. Berenguer J, Bellón JM, Miralles P, Alvarez E, Sánchez Conde M, Cosín J, López JC, Catalán P, Alvarez F, Resino S. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007; 14 (12): 859-869 (A; FI =2.97).

16. Micheloud D, Jensen J, Bellón JM, Gonzalez R, Mellado MJ, Navarro ML, Muñoz-Fernández MA, Resino S. Long-term response to highly active anti-retroviral therapy in human inmunodeficiency virus and hepatitis C virus coinfected children: 6 years of follow-up. Pediatr Infect Dis J 2007; 26(11):1061-1064. (A; FI =3.08).

17. Micheloud D, Jensen J, Bellón JM, Gurbindo MD, de José MI, Moreno D, Ramos JT, Muñoz-Fernández MA, Resino S. Slow progression of HIV-1 and HCV disease on a cohort of HIV-1/HCV coinfected children. Pediatr Infect Dis J 2007; 26(9):846-849. (A; FI =3.08).

18. Resino S; Bellón JM; León JA; Martín Fontelos P, Navarro ML, Ramos JT, Resino, R, Muñoz-Fernández MA. Viral load in HIV-infected children on high activity antiretroviral therapy. Med Clin (Barc). 2007; 128 (2): 49-51. Spanish (A; FI =1.32).

19. Bermejo-Martin JF, Alonso A, Garcia-Arevalo M, de Lejarazu RO, Pino M, Resino S, Tenorio A,  Bernardo D, León AJ , Garrote JA, Ardura J, Dominguez-Gil M, Eiros J, Blanco-Quiros A, Kelvin D, Munoz-Fernandez MA; Arranz E. Persistence of pro-inflammatory responses after Respiratory Syncytial Virus severe disease in children. J Allergy Clin Immunol 2007; 119(6):1547-50. (L; FI =8.11).

20. Resino S, Pérez A, Seoane E, Serrano D, Berenguer J, Balsalobre P, Fernández G, Diez JL, and Muñoz-Fernández MA. Immune reconstitution after autologous peripheral blood stem cell transplantation in HIV-infected patients: Might be better than expected?. AIDS Res Hum Retrov 2007; 23 (4): 543-548. (A; FI =2.02).

21. Pérez A, Gurbindo MD, Resino S, Aguarón A, and Muñoz-Fernández MA. NK Cell Increase in Neonates from the Preterm to the Full-Term Period of Gestation. Neonatology 2007; 92(3):158-163. (A; FI =1.90).

22. Correa R, Harari A, Vallelian F, Resino S, Munoz-Fernandez MA and Pantaleo G. Functional patterns of HIV-1-specific CD4 T-cell responses in vertically HIV infected children are substantially influenced by the extent of virus suppression and exposure. AIDS 2007; 21(1):23-30 (A; FI =5.84).

2006:

23. Bermejo-Martin JF, Bernardo D, Dominguez-Gil M, Alonso A, Garcia-Arevalo M, Pino M, Ortiz de Lejarazu R, Eiros JM, Ardura J, León AJ, Garrote JA, Resino S, Blanco-Quiros A, Munoz-Fernandez MA, Blanco-Quirós A, Arranz E. IL-1b, IL-8, IL-6 in nasal secretions: a common role of the innate immunity in viral bronchial infections in infants?. Br J Biomed Sci 2006, 63(4):173-5 (A; FI =0.55).

24. Resino S, Seoane E, Perez A, Ruiz-Mateos E, Leal M, and Muñoz-Fernández MA. Different profile of immune reconstitution after HAART in HIV-infected children and adults. BMC Inf Dis 2006, 6(1):112 (A; FI =1.89).

25. Navarro ML, Resino S, González Sánchez MI, and Muñoz-Fernández MA. Immune restoration disease secondary to hepatitis C virus in a HIV-infected pediatric patient. Med Clin (Barc) 2006; 126 (13): 518-519. Spanish (CR; FI =1.32).

26. Resino S; Larru B; Bellon J, Resino R; de José MI; Gurbindo Gutiérrez MD; Léon JA; Mellado MJ; Ramos JT; Muñoz-Fernández MA. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. BMC Inf Dis 2006, 6(1):107 (A; FI =1.89).

27. Resino S; Seoane E, Gurbindo Gutiérrez MD; Léon JA; and Muñoz-Fernández MA. CD4⁺ T-cells immunodeficiency is more dependent of immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 42(3):269-276 (A; FI =3.94).

28. Resino S, Resino R, Bellón JM, Micheloud D, Gurbindo MD, de José MI, Ramos JT, Martín Fontelos P, Ciria L, and Muñoz-Fernández MA. Clinical outcomes improve with the highly active antiretroviral therapy in vertically HIV-1 infected children. Clin Infect Dis 2006; 45: 243-252 (A; FI =6.18).

29. Resino S; Alvaro-Meca A; de José MI; Martin-Fontelos P; Gurbindo Gutiérrez MD; Léon JA; Ramos JT; Ciria L; Muñoz-Fernández MA. Low immunological response to highly active antiretroviral therapy in naive vertically HIV-1 infected children with severe immunodeficiency. Pediatr Infect Dis J 2006; 25(4):365-368. (A; FI =3.21).

30. Resino S.; Perez A, León JA; Gurbindo MD; and Muñoz-Fernández MA. Plasma interleukin-7 levels before highly active antiretroviral therapy may predict CD4+ T-cells recovery and virological failure in HIV-infected children. J Antimicrob Chemoth 2006; 57(4):798-800. (L; FI =3.89).

31. Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez MD; Léon JA; Ramos JT; Ciria L; de José MI; Mellado MJ; Muñoz-Fernández MA. Long-term effects of highly active antiretroviral therapy in pre-treated vertically HIV-1 infected children: 6 years of follow-up. Clin Infect Dis 2006; 42(6):862-9. (A; FI =6.18).

32. Resino S; Bellón JM; Muñoz-Fernández MA, and the Spanish Group of Pediatric HIV Infection. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-children with severe-moderate immunodeficiency. J Antimicrob Chemoth 2006; 57: 579-582 (L; FI =3.89).

33. Resino S; Resino R; Léon JA; Bellón JM; Martin-Fontelos P; Ramos JT; Gurbindo Gutiérrez MD; de José MI; Ciria L; Muñoz-Fernández MA. Impact of long-term viral suppression in CD4+ recovery of HIV-children on highly active antiretroviral therapy. BMC Infect Dis 2006; 24;6(1):10 (doi:10.1186/1471-2334-6-10). (A; FI =1.89).

34. Berenguer J, Pérez-Elías MJ, Bellón JM, Knobel H, Rivas-González P, Gatell JM; Mígueles M, Hernández-Quero J, Flores J, Soriano V, Santos I, Podzamczer D, Sala M. Camba M, Resino S. Effectiveness and safety of abacavir, lamivudine and zidovudine in antiretroviral-naïve HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr 2006; 41(2):154-159. (A; FI =3.94).

2005:

35. ^(*)Jiménez JL, Resino S; Martinez-Colom A; Bellón JL; Muñoz-Fernández MA. Mutations at codons 54 and 82 of HIV-protease predict virological response of HIV-infected children on salvage lopinavir-ritonavir therapy. J Antimicrob Chemoth 2005, 56(6):1081-1086 (A; FI =3.88). (^(*) José Luis Jimenez and Salvador Resino have equally contributed to this work).

36. Resino S, Galán I, Pérez A, Ramos JT, Bellón, JM, Martín Fontelos, P, de José, MI, Gurbindo MD, Cabrero E, Muñoz-Fernández MA. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. AIDS Res Hum Retrov 2005, 21 (5): 398-406. (A; FI =2.53).

37. Resino S, Alvaro-Meca A, de José MI, Gurbindo MD, Ramos JT, Martin-Fontelos P, and Muñoz-Fernández MA. Lopinavir/r versus nelfinavir as salvage therapy.HHH. Pediatr Infect Dis J 2005, 24 (4): 392-393. (L; FI =3.05).

38. Resino S, Galán I, Correa R, Pajuelo L, Bellón JM, and Muñoz-Fernández MA. Homeostatic role of IL-7 in HIV-1 infected children on HAART: Association with immunological and virological parameters. Acta Paediatr 2005, 94 (2): 170-177. (A; FI =1.27).

2004:

39. Resino S, Bellón JM, Ramos JT, González-Rivera M, De José MI, González MI, Gurbindo MD, Mellado MJ, Cabrero E, and Muñoz-Fernández MA. Positive virologic outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children. A prospective cohort study. J Antimicrob Chemoth 2004, 54 (5): 921-931. (A; FI =3.88).

40. Resino S, Bellón JM, Ramos JT, Navarro ML, Martín-Fontelos P, Cabrero E, and Muñoz-Fernández MA. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus infected children. Pediatr Infect Dis J 2004, 23 (10): 923-930. (A; FI =2.73).

41. Resino S, Bellón JM, Ramos JT, Resino R, Gurbindo D, Mellado MJ, de Jose MI, and Muñoz-Fernández MA. Impact of highly active antiretroviral therapy on CD4+ T-cells and viral load of children with AIDS: a populational study. AIDS Res Hum Retrov 2004, 20 (9): 927-931. (A; FI =2.37).

42. Resino S, Pérez A, Galán I, Bellón JM, and Muñoz-Fernández MA. Changes in CD4+ and CD8+ T-cell subsets in HIV-infected children differently correlate with replication viral and thymic function. Med Clin (Barc) 2004; 123 (14): 527-531. Spanish (A; FI =1.00).

43. Resino S, Bellón JM, Perez, A, Gurbindo MD, and Muñoz-Fernández MA. Subsets of CD8+ T cells in long-term asymptomatic vertically HIV-1 infected children. Med Clin (Barc) 2004; 122 (1): 6-11. Spanish (A; FI =1.00).

44. Resino S, Galán I, Pérez A, León JA, Gurbindo MD, Seoane E y Muñoz-Fernández MA. HIV-infected children with moderate-severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol 2004, 137: 570-577 (A; FI =2.51).

45. ^(*) Resino S, Rivero L, Ruiz-Mateos E, Galán I, Muñoz Franco J, Muñoz-Fernández, MA, and Leal M. Immunity in HIV-1 infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4+ T cell after highly active antiretroviral therapy. J Clin Immunol 2004; 24 (4): 379-388. (A; FI =2.36). (^(*) Salvador Resino and Laura Rivero have equally contributed to this work)

46. Resino S, Bellón JM, Resino R, Navarro ML, Ramos JT, Mellado MJ, de Jose MI, and Muñoz-Fernández MA. Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004; 38: 1605-1612. (A; FI =5.59).

47. Galán I, Jiménez JL, González-Rivera M, De José MI, Navarro ML, Ramos JT, Mellado MJ, Gurbindo MD, Bellón JM, Resino S, Cabrero E, and Muñoz-Fernández MA. Virological phenotype switch under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 2004; 18: 247-255. (A; FI =5.89).

48. Resino S, Bellón JM, Gurbindo D, and Muñoz-Fernández MA. CD38 in CD8+ T cells predict virological failure in HIV-infected children reciving antiretroviral therapy. Clin Infect Dis 2004; 38 (3): 412-17 (A; FI =5.59).

2003:

49. Resino S, Bellón JM, Gurbindo D, Ramos JT, León JA, Mellado MJ, and Muñoz-Fernández MA. Viral Load and CD4+ T Lymphocyte Response to Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1Infected Children: An Observational Study. Clin Infect Dis 2003, 37: 1216-1225 (A; FI =5.39).

50. Sánchez-Ramón S, Resino S, Bellón JM, Ramos JT, Gurbindo D, and Muñoz-Fernández MA. Neuroprotective Effects of early antiretroviral therapy in vertically HIV-1-infected children. Pediatr Neurol 2003; 29: 218-221 (A; FI =1.24).

51. Correa R, Resino S, and Muñoz-Fernández MA. Increased Interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected Children. J Clin Immunol 2003, 23 (5): 401-406 (A; FI =2.59).

52. Resino S, Galán I, Bellón JM, Navarro ML, León JA, and Muñoz-Fernández MA. Characterising the immune system after long-term undetectable viral load in HIV-1-infected children. J Clin Immunol 2003, 23 (4): 279-289 (A; FI =2.59).

53. Resino S, Sánchez-Ramón S, Correa R, Bellón JM, Navarro ML, and Muñoz-Fernández MA. Complete immune and clinical recovery after highly active antiretroviral therapy can be achieved in advanced vertically HIV-1 infected children. Med Clin (Barc) 2003, 120 (11): 417-420. Spanish (CR; FI =1.01).

54. Resino S, Bellón JM, Gurbindo D, León JA, and Muñoz-Fernández MA. Recovery of T-cell subsets after antiretroviral therapy in HIV-infected children. Eur J Clin Invest 2003, 33 (7): 619-627 (A; FI =2.34).

55. Resino S, Correa R, Bellón JM, and Muñoz-Fernández MA. Preserved Immune System in Long-Term Asymptomatic Vertically HIV-1 Infected Children. Clin Exp Immunol 2003, 132 (1): 105-112 (A; FI =2.34).

56. Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, and Muñoz-Fernández MA. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children. Pediatrics 2003, 111 (2): e168-e175. (A; FI =3.78).

57. Resino S, Bellón JM, Sánchez-Ramón S, Gurbindo D, León JA, and Muñoz-Fernández MA. CD8+ T-cells predict viral response to highly active antiretroviral therapy in HIV-1-infected children. Pediatr Res 2003, 53 (2): 309-312. (A; FI =3.06).

58. Resino S, Abad ML, Navarro J, Bellón JM, Sánchez-Ramón S and Muñoz-Fernández MA. Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clin Exp Immunol 2003, 131 (1): 130-137 (A; FI =2.34).

2002:

59. Resino S, Correa R, Bellón JM, Sánchez-Ramón S, and Muñoz-Fernández MA. Characterizing immune reconstitution after long-term HAART in pediatric AIDS. AIDS Res Hum Retrov 2002, 18 (18): 1395-1406 (A; FI =2.27).

60. Resino S, Bellón JM, Gurbindo D, Ramos JT, León JA, and Muñoz-Fernández MA. Dynamics of progression markers in a non-study population of HIV-1 vertically infected infants with different antiretroviral treatments. Acta Paediatr 2002, 91 (7): 776-782 (A; FI =1.26).

61. Resino S, Bellón JM, Gurbindo D, Ramos JT, León JA y Muñoz-Fernández MA. Responses to antiretroviral treatments in vertically HIV-1-infected children. Med Clin (Barc) 2002, 119 (19): 725-729. Spanish (A; FI =0.85).

62. Punzón C, Resino S, Bellón JM, Muñoz-Fernández MA and Fresno M. Analysis of the systemic immune response in human immunodeficiency infected (HIV)-1 patients suffering opportunistic Candida infection. Eur Cytokine Netw 2002, 13 (2): 215-223 (A; FI =2.15).

63. Resino S, Bellón JM, Gurbindo D, Ramos JT, Mª Luisa Navarro, León JA, Clemente J y Muñoz-Fernández MA. Immunologic Recovery After 2-Years on HAART In vertically HIV-Infected Children. Med Clin (Barc) 2002, 118 (16): 601-604. Spanish (A; FI =0.85).

64. Resino S, Bellón JM, Sánchez-Ramón S, Gurbindo D, Ruíz-Contreras J, León JA, Ramos JT and Muñoz-Fernández MA. Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch Dis Child 2002; 86: 119-124 (A; FI =2.1).

65. Resino S, Abad ML, Bellón JM, Gurbindo D, León JA y Muñoz-Fernández MA. Different immune profiles according to the immunological and clinical progression in vertically HIV-infected children. Med Clin (Barc) 2002, 118 (7): 241-246. Spanish (A; FI =0.85).

66. Resino S, Sánchez-Ramón S, Bellón JM, Correa R, Abad ML, and Muñoz-Fernández MA. Immunological Recovery After 3 Years’ Of Antiretroviral Therapy In HIV-Infected Children. AIDS 2002; 16 (3): 483-486. (L; FI =5.98). .

2001:

67. Gironés N, Rodríguez C, Basso B, Bellon JM, Resino S, Muñoz-Fernandez MA, Gea S, Iosa D, Moretti E and Fresno M. Antibodies to an epitope from the Cha Human Autoantigen are a marker of Chagas’ Disease. Clin Diagn Lab Immun 2001; 8 (6): 1039-1043. (A; FI =1.48).

68. Resino S, Bellón JM, Gurbindo D and Muñoz-Fernández MA. Dysruption in cytokine and chemokine production by T cells in vertically HIV-1 infected children. Acta Paediatr, 2001; 90 (9): 989-997. (A; FI =1.58).

69. González-Nicolás J, Resino S, Jiménez JL, Alvarez S, Fresno M, and Muñoz-Fernández. MA. TNF-a and nitric oxide in vertically HIV-1-infected children: Implications for pathogenesis. Eur Cytokine Netw 2001; 12 (3): 437-444. (A; FI =1.66).

70. Resino S, Navarro J, Bellón JM, Gurbindo D, León JA and Muñoz-Fernández MA. Naïve and memory CD4+ T-cells and T-cell activation markers in HIV-1 infected children on HAART. Clin Exp Immunol 2001; 125:266-273. (A; FI =2.71).

71. Resino S, Navarro J, Bellón JM, Gurbindo D, León JA y Muñoz-Fernández MA. Relationship between T-cells subsets and prognostic markers in HIV-1-infected children. Med Clin (Barc) 2001; 117(6): 201-206. Spanish (A; FI =0.84).

72. Resino S, Sánchez-Ramón S, Bellón JM, Jiménez JL, Gurbindo D and Muñoz-Fernández MA. Impaired IL-5 production by T cells as prognostic marker of disease progression in HIV-1-infected children. Eur Cytokine Netw 2001; 12 (2) 253-259 (A; FI =1.66).

73. Navarro J, Resino S, Bellón JM, Abad ML, Gurbindo D, Fernández-Cruz E and Muñoz-Fernández MA. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV-1 infection in children treated with highly active antiretroviral therapy. AIDS Res Hum Retrov 2001; 17 (6) 525-532. (A; FI =2.52).

2000:

74. Alonso R, Resino S, Bellón JM, and Muñoz-Fernández MA. Antiretroviral treatment induces a shift to type-2 cytokine responses in HIV-1 infected pregnant women. Eur Cytokine Netw 2000; 11: 647-653. (A; FI =1.69).

75. Resino S, Bellón JM, Sánchez-Ramón S, Gurbindo D and Muñoz-Fernández MA. Clinical relevance of cytokine production in HIV-1-infection in children on antiretroviral therapy. Scand J Immunol 2000; 52: 634-640. (A; FI =1.77).

76. Resino S, Bellón JM, Gurbindo D, Ramos JT, Ruíz-Contreras J y Muñoz-Fernández MA. Prognostic markers of progression to aids in infants vertically infected by human immunodeficiency virus type-1. Med Clin (Barc) 2000; 115: 564-567. Spanish (A; FI =0.75).

77. Resino S, Gurbindo MD, Bellón Cano JM, and Muñoz-Fernández MA. Predictive markers of clinical outcome in vertically HIV-1 infected infants. A prospective longitudinal study. Pediatr Res 2000; 47: 509-15. (A; FI =2.79).

78. Resino S, Bellón JM, Jiménez JL, Gurbindo MD y Muñoz-Fernández MA. Role of the cytokines and the chemokines in the non-progression of the hiv-1 infection in vertically infected children. Med Clin (Barc) 2000; 114(17): 641-6. Spanish (A; FI =0.75).

1999:

79. Gurbindo D, Resino S, Sánchez-Ramón S, León JA and Muñoz-Fernández MA. Correlation of viral load and CD8 T-lymphocyte with development of neurological manifestations in vertically HIV-infected infants. A prospective longitudinal study. Neuropediatrics 1999; 30: 197-204. (A; FI =1.67).

80. Resino S, Jiménez JL, Gurbindo D y Muñoz-Fernández MA. Prognostic markers of survival in infants younger than twelve months of age vertically infected by human immunodeficiency virus type-1. Med Clin (Barc) 1999; 113: 561-566. Spanish A; FI =0.81).

81. Resino S, Gurbindo D, Bellón JM, Jiménez JL, León JA, Navarro J y Muñoz-Fernández MA. Dinamics of Inmunoglobulins production in infected children born to HIV-1 infected mothers: effect of zidovudine. Med Clin (Barc) 1999; 112: 568-71. Spanish (A; FI =0.81).

Posts relacionados:

• Redacción y gestión de documentos científicos
• Publicaciones no incluidas en el JCR (ISI)
• Publicaciones internacionales
• Publicaciones científicas
• Proyectos: colaboraciones